IRVING, TX--(Marketwired - July 01, 2013) -
BioTech Medics, Inc., (PINKSHEETS: BMCS
) announced that it has signed a $5 million U.S. cross-marketing licensing non-exclusive contract for its patented SHBAN Alcohol Free Persistent Hand & Body Sanitizer with LifeBionix, Inc. The agreement includes cash and ongoing royalties payable to BioTech over a five year term anticipated to start third quarter 2013 without dilution of BioTech stock.
LifeBionix is a privately owned company that has funding pending through an Irish Section 110-SPV private investment fund, utilizing a Qualifying Investor Fund (QIF). Ireland has become a popular jurisdiction for SPV's for structured finance transactions. Ireland's extensive double tax treaty network and onshore EU status make it a location of choice for expansion capital.
The US market demand for Hand Sanitizers is increasing for non-alcoholic products, according to GIA Research. "Private label brands continue to dominate the market. The US Hand Sanitizer sales are projected to reach US$226.3 million by 2018. Improving knowledge on Hand Care are presently driving the market for new sanitizers."
SHBAN is superior to alcohol gel because it is long-lasting up to 4 hours according to laboratory tests. If you have wondered why people who use alcohol gels still get colds and flu viruses it is because gels with 60% to 65% alcohol kill 99.9% of germs, but may not kill cold and flu viruses. It is dangerous to carry around alcohol gels with higher alcohol content because alcohol gels are a Class I fire hazard. Additionally, the Poison Control centers have reported over 22,000 poisonings from ingesting alcohol gels. Independent tests show SHBAN's active ingredient inhibits the Norovirus, Swine H1N1 and H5N1 Influenza A viruses.
SHBAN is gentle on hands. SHBAN can be used on a cotton swab in your nostrils. Studies indicate that 80% of viruses are inhaled. SHBAN is economical. One (1) ounce of SHBAN is equal six (6) ounces of alcohol gel. SHBAN is available online: www.shban.com.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties; actual results could differ materially from those expressed. The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease.